Analysts Set Definitive Healthcare Corp. (NASDAQ:DH) Price Target at $3.27

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have been given a consensus recommendation of “Reduce” by the ten analysts that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $3.2714.

A number of research firms have recently commented on DH. Stephens lowered their target price on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. Wall Street Zen upgraded Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Canaccord Genuity Group lowered their target price on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating for the company in a research note on Friday, February 27th. Finally, Zacks Research cut Definitive Healthcare from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 5th.

Definitive Healthcare Trading Up 1.9%

DH opened at $1.05 on Friday. The stock has a market cap of $109.69 million, a PE ratio of -0.84, a PEG ratio of 90.03 and a beta of 1.60. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.41. The business has a 50 day moving average of $1.22 and a 200-day moving average of $2.14. Definitive Healthcare has a 52 week low of $0.92 and a 52 week high of $4.70.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in shares of Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after purchasing an additional 7,404,363 shares during the period. Dimensional Fund Advisors LP raised its stake in Definitive Healthcare by 1.6% during the third quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock valued at $8,417,000 after buying an additional 33,612 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Definitive Healthcare by 11.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock valued at $4,937,000 after buying an additional 127,055 shares during the last quarter. Bank of America Corp DE raised its stake in Definitive Healthcare by 23.7% during the second quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock valued at $3,001,000 after buying an additional 147,599 shares during the last quarter. Finally, Inspire Investing LLC raised its stake in Definitive Healthcare by 505.7% during the fourth quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock valued at $2,006,000 after buying an additional 583,562 shares during the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.